

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5228170

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
PAUL EDWARD MAY	08/21/2018
CHUNG CHAN THAM	09/06/2018
LEWIS READING	08/16/2018
CLIVE BUCKBERRY	09/11/2018
EDUARDO ESSER	09/11/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	QUANTA DIALYSIS TECHNOLOGIES LTD.
<b>Street Address:</b>	UNIT 5, THYTHING ROAD
<b>Internal Address:</b>	ARDEN FOREST INDUSTRIAL ESTATE, ALCESTER
<b>City:</b>	WARWICKSHIRE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	B49 6EU
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16077170
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2124796338
<b>Email:</b>	zIPPatentDocketingMailboxUS@cooley.com
<b>Correspondent Name:</b>	BRIAN P. HOPKINS
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE NW, SUITE 700
<b>Address Line 2:</b>	COOLEY LLP
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	QNTA-007N01US 327922-2015
<b>NAME OF SUBMITTER:</b>	BRIAN P. HOPKINS
<b>SIGNATURE:</b>	/BRIAN P. HOPKINS/
<b>DATE SIGNED:</b>	11/08/2018

**Total Attachments: 8**

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page1.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page2.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page3.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page4.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page5.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page6.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page7.tif

source=QNTA\_007\_N01US\_ASSIGNMENT\_EXECUTED#page8.tif

ASSIGNMENT

Paul Edward MAY; Chung Chan THAM; Lewis READING; Clive BUCKBERRY; and Eduardo ESSER, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled MEMBRANE PUMP USAGE CONDITION DETECTION, and which is a:

- (1) ☐ provisional application
  - (a) ☐ to be filed herewith; or
  - (b) ☐ bearing Application No. , and filed on ;
- (2) ☒ non-provisional application
  - (a) ☐ to be filed herewith; or
  - (b) ☒ bearing Application No. 16/077,170, and filed on August 10, 2018; and/or
- (3) ☒ PCT application
  - (a) ☒ bearing Application No. PCT/GB2017/050235, and filed on January 31, 2017.

and/or
- (4) ☐ attached hereto.

**WHEREAS**, Quanta Dialysis Technologies Ltd., a having its principal place of business at Unit 5, Thything Road, Arden Forest Industrial Estate, Alcester, WARWICKSHIRE, B49 6EU, UNITED KINGDOM, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

**NOW, THEREFORE**, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by

these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and

Attorney Docket No. QNTA-007/N01US 327922-XXXX


that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

21/Aug/2018  
Date

  
Paul Edward May

Witness:

21/Aug/2018  
Date

  
NATALIE LUCKEN

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Chung Chan Tham

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Lewis Reading

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Paul Edward May

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

06 Sept 2018

\_\_\_\_\_  
Chung Chan Tham

*Chung Chan Tham*

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

6-10-2018

\_\_\_\_\_  
MS Abraham

*MS Abraham*

\_\_\_\_\_  
Date

\_\_\_\_\_  
Lewis Reading

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date Paul Edward May  
Witness: \_\_\_\_\_

\_\_\_\_\_  
Date  
\_\_\_\_\_  
Date

\_\_\_\_\_  
Date Chung Chan Tham  
Witness: \_\_\_\_\_

\_\_\_\_\_  
Date  
\_\_\_\_\_  
Date

16/08/2018  
\_\_\_\_\_  
Date Lewis Reading

Witness: \_\_\_\_\_  
16/08/2018  
\_\_\_\_\_  
Date

\_\_\_\_\_  
Date



11th September 2018  
Date

Clive Buckberry  
Clive Buckberry

Witness:

11th September 2018  
Date

Michael J. J. J.

Date

11th September 2018  
Date

Eduardo Esser  
Eduardo Esser

Witness:

11th September 2018  
Date

Michael J. J. J.


Date

Attorney Docket No. QNTA-007/N01US 327922-XXXX


For and on behalf of ASSIGNEE:

Date: 14th September 2018

By:

  
Name: SOUAD E. MILLAD  
Title: CEO  
Company: Quanta Dialysis Technologies  
Ltd.

Witness:

  
Signature

14th September 2018  
Date

MARK WALLACE  
Printed name